Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $193,390.74 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Centessa Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ CNTA opened at $16.91 on Friday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -11.05 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12-month low of $7.38 and a 12-month high of $18.97. The firm’s 50-day simple moving average is $16.77 and its 200 day simple moving average is $15.04.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals during the third quarter valued at $2,834,000. Wellington Management Group LLP bought a new position in Centessa Pharmaceuticals in the third quarter valued at approximately $1,609,000. Nantahala Capital Management LLC bought a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth $4,064,000. State Street Corp bought a new stake in Centessa Pharmaceuticals in the third quarter valued at about $777,000. Finally, Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals in the third quarter valued at about $4,951,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of recent analyst reports. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.